Cover Image

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC.Methods: A con...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaomi Li (Author), Jingyan Wang (Author), Xiaoyan Ding (Author), Yawen Xu (Author), Minghua Yu (Author), Hongxiao Wu (Author), Na Deng (Author), Wei Li (Author), Jinglong Chen (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
by: Chen B, et al.
Published: (2022)

Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review
by: Cheng Xue, et al.
Published: (2024)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022)
by: Cong-Cong Wang, et al.
Published: (2023)

Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
by: Hye Won Lee
Published: (2022)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
by: Yukari Matsumoto, et al.
Published: (2022)

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma
by: Rachel Sally, BA, et al.
Published: (2021)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
by: Landon L. Chan, et al.
Published: (2024)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
by: Young-Hwan Ahn, et al.
Published: (2022)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023)

Hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
by: Camillo Porta
Published: (2011)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma
by: Pengfei Zhang, et al.
Published: (2022)

Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
by: Junji Furuse, et al.
Published: (2023)

Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
by: Takamasa Ohki, et al.
Published: (2020)

Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
by: Lung-Yi Mak
Published: (2024)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level
by: Shao W, et al.
Published: (2015)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
by: Ye Zheng, et al.
Published: (2022)

Comprehensive Identification of Bridge Genes to Explain the Progression from Chronic Hepatitis B Virus Infection to Hepatocellular Carcinoma
by: Nong W, et al.
Published: (2021)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
by: Qing-Yun Xie, et al.
Published: (2022)

Effects of three flavonoids on the metabolism of lenvatinib
by: Jinzhao Yang, et al.
Published: (2024)

C-reactive Protein Overexpression in the Background Liver of Hepatitis B Virus-Associated Hepatocellular Carcinoma Is a Prognostic Biomarker
by: Jin Ho Shin, et al.
Published: (2018)

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway
by: Yilan Huang, et al.
Published: (2024)

What is the role of Von Willebrand factor in chronic hepatitis B virus infection to hepatocellular carcinoma: a review article
by: Qiong Xiang, et al.
Published: (2022)

A single hepatic mass with two tales: hepatic tuberculosis and hepatocellular carcinoma
by: Yi De Ian Koh, et al.
Published: (2023)

Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.
by: Yuan-Kuan Li, et al.
Published: (2023)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
by: Yadong Wang, et al.
Published: (2022)

How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data
by: Yanyan Liu, et al.
Published: (2023)

Risk Factors and Comorbidities Associated With Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection
by: Helen Weidemann, et al.
Published: (2024)

MicroRNA 21as a novel biomarker in hepatitis C virus-related hepatocellular carcinoma
by: Maha Assem Hussein, et al.
Published: (2022)

Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma
by: Mai R, et al.
Published: (2020)

SCORING MODELS FOR PREDICTING HEPATOCELLULAR CARCINOMA RISK IN HCV PATIENTS AFTER ANTIVIRAL THERAPY
by: Oana Irina Gavril, et al.
Published: (2023)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
by: Blair McNamara, et al.
Published: (2023)